Eric E Klein

List of Publications by Year
in descending order

321 papers	25,765 citations	10986 71 h-index	7348 152 g-index
331 all docs	331 docs citations	331 times ranked	25558 citing authors

#	Article	IF	Citations
1	5Î±-Reductase Inhibitors Are Associated with Reduced Risk of SARS-CoV-2 Infection: A Matched-Pair, Registry-Based Analysis. Journal of Urology, 2022, 207, 183-189.	0.4	7
2	Reply by Authors. Journal of Urology, 2022, 207, 189.	0.4	0
3	Influence of Enema and Dietary Restrictions on Prostate MR Image Quality: A Multireader Study. Academic Radiology, 2022, 29, 4-14.	2.5	18
4	125I Interstitial brachytherapy with or without androgen deprivation therapy among unfavorable-intermediate and high-risk prostate cancer. Brachytherapy, 2022, 21, 85-93.	0.5	3
5	Gut Microbiomeâ€"Dependent Metabolic Pathways and Risk of Lethal Prostate Cancer: Prospective Analysis of a PLCO Cancer Screening Trial Cohort. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 192-199.	2.5	18
6	Genetic factors associated with prostate cancer conversion from active surveillance to treatment. Human Genetics and Genomics Advances, 2022, 3, 100070.	1.7	10
7	Validating the association of adverse pathology with distant metastasis and prostate cancer mortality 20-years after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 104.e1-104.e7.	1.6	4
8	Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for â€œlargeâ€•cribriform prostatic adenocarcinoma. Modern Pathology, 2022, 35, 1092-1100.	5.5	10
9	Multicancer early detection. Clinical Chemistry and Laboratory Medicine, 2022, .	2.3	0
10	Transperineal Prostate Biopsy is Associated With Lower Tissue Core Pathogen Burden Relative to Transrectal Biopsy: Mechanistic Underpinnings for Lower Infection Risk in the Transperineal Approach. Urology, 2022, , .	1.0	5
11	Hypoxia-Reoxygenation Couples 3Î²HSD1 Enzyme and Cofactor Upregulation to Facilitate Androgen Biosynthesis and Hormone Therapy Resistance in Prostate Cancer. Cancer Research, 2022, 82, 2417-2430.	0.9	4
12	Variation in Molecularly Defined Prostate Tumor Subtypes by Self-identified Race. European Urology Open Science, 2022, 40, 19-26.	0.4	7
13	The Promise of Multicancer Early Detection. Comment on Pons-Belda et al. Can Circulating Tumor DNA Support a Successful Screening Test for Early Cancer Detection? The Grail Paradigm. Diagnostics 2021, 11, 2171. Diagnostics, 2022, 12, 1243.	2.6	11
14	Elevated IsoPSA Selects for Clinically Significant Prostate Cancer Without a Preference for Any Particular Adverse Histopathologic or Radiographic Feature.. Urology, 2022, , .	1.0	1
15	Clinical validation of IsoPSA, a single parameter, structure-focused assay for improved detection of prostate cancer: A prospective, multicenter study. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 408.e9-408.e18.	1.6	3
16	Detection of Clinically Significant Index Prostate Cancer Using Micro-ultrasound: Correlation With Radical Prostatectomy. Urology, 2022, 169, 150-155.	1.0	1
17	Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer. Clinical Cancer Research, 2021, 27, 320-329.	7.0	46
18	A novel imaging based Nomogram for predicting post-surgical biochemical recurrence and adverse pathology of prostate cancer from pre-operative bi-parametric MRI. EBioMedicine, 2021, 63, 103163.	6.1	32

#	Article	IF	Citations
19	Prostate cancer in young men represents a distinct clinical phenotype: gene expression signature to predict early metastases. , 2021, 5, 50-61.		1
20	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics, 2021, 53, 65-75.	21.4	264
21	A comparative study of PCS and PAM50 prostate cancer classification schemes. Prostate Cancer and Prostatic Diseases, 2021, 24, 733-742.	3.9	14
22	Editorial Comment. Journal of Urology, 2021, 205, 460-460.	0.4	0
23	Androgen Deprivation Therapy in Men with Prostate Cancer Does Not Affect Risk of Infection with SARS-CoV-2. Journal of Urology, 2021, 205, 441-443.	0.4	44
24	GPS Assay Association With Long-Term Cancer Outcomes: Twenty-Year Risk of Distant Metastasis and Prostate Cancerâ€“Specific Mortality. JCO Precision Oncology, 2021, 5, 442-449.	3.0	10
25	Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8â€10) prostate cancer treated primarily by radical prostatectomy. Cancer, 2021, 127, 1425-1431.	4.1	10
26	Discovery and fine-mapping of height loci via high-density imputation of GWASs in individuals of African ancestry. American Journal of Human Genetics, 2021, 108, 564-582.	6.2	18
27	Multicenter Comparison of 17-Gene Genomic Prostate Score as a Predictor of Outcomes in African American and Caucasian American Men with Clinically Localized Prostate Cancer. Journal of Urology, 2021, 205, 1047-1054.	0.4	7
28	Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer. Journal of Clinical Investigation, 2021, 131, .	8.2	17
29	Hexose-6-phosphate dehydrogenase blockade reverses prostate cancer drug resistance in xenograft models by glucocorticoid inactivation. Science Translational Medicine, 2021, 13, .	12.4	20
30	A prespecified interim analysis of the PATHFINDER study: Performance of a multicancer early detection test in support of clinical implementation.. Journal of Clinical Oncology, 2021, 39, 3070-3070.	1.6	9
31	Androgen regulation of pulmonary AR, TMPRSS2 and ACE2 with implications for sex-discordant COVID-19 outcomes. Scientific Reports, 2021, 11, 11130.	3.3	68
32	Computer extracted gland features from H&E predicts prostate cancer recurrence comparably to a genomic companion diagnostic test: a large multi-site study. Npj Precision Oncology, 2021, 5, 35.	5.4	13
33	Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA. Clinical Cancer Research, 2021, 27, 4221-4229.	7.0	61
34	The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice. Cancers, 2021, 13, 3501.	3.7	50
35	Management of a Prostate Cancer Patient With Inherited Germline BRCA1 and BRCA2 Mutations: A Case Report. Urology, 2021, 153, 129-131.	1.0	0
36	Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. JAMA Network Open, 2021, 4, e2115312.	5.9	12

#	Article	IF	Citations
37	Pitfalls in Prostate MRI Interpretation: A Pictorial Review. Seminars in Roentgenology, 2021, 56, 391-405.	0.6	1
38	Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. European Urology, 2021, 80, 142-146.	1.9	12
39	Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort. Journal of Urology, 2021, 206, 1147-1156.	0.4	14
40	Reply by Authors. Journal of Urology, 2021, 206, 1156.	0.4	0
41	Androgen Deprivation Therapy in Men with Prostate Cancer Does Not Affect Risk of Infection with SARS-CoV-2. Reply.. Journal of Urology, 2021, 206, 785-785.	0.4	25
42	Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. Urology, 2021, 155, 165-171.	1.0	11
43	Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomographyâ€"Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. JAMA Network Open, 2021, 4, e2138550.	5.9	18
44	Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. European Urology, 2020, 77, 3-10.	1.9	18
45	Impact of using 29ÂMHz high-resolution micro-ultrasound in real-time targeting of transrectal prostate biopsies: initial experience. World Journal of Urology, 2020, 38, 1201-1206.	2.2	42
46	Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. Prostate Cancer and Prostatic Diseases, 2020, 23, 136-143.	3.9	36
47	A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. Journal of the National Cancer Institute, 2020, 112, 1003-1012.	6.3	59
48	Clinicopathologic features and outcomes of anterior-dominant prostate cancer: implications for diagnosis and treatment. Prostate Cancer and Prostatic Diseases, 2020, 23, 435-440.	3.9	11
49	Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 1474-1494.	1.6	141
50	Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 lowÂdose rate brachytherapy monotherapy. Brachytherapy, 2020, 19, 43-50.	0.5	15
51	The Association of Urologic Oncology Fellowship Training and Diagnostic Yield of Prostate Biopsy. Urology, 2020, 137, 115-120.	1.0	1
52	Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. JCO Precision Oncology, 2020, 4, 1228-1238.	3.0	2
53	Surgical management of high-risk, localized prostate cancer. Nature Reviews Urology, 2020, 17, 679-690.	3.8	20
54	Heterogenous Dose-escalated Prostate Stereotactic Body Radiation Therapy for All Risk Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 469-476.	1.3	2

#	Article	IF	Citations
55	A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry. European Urology, 2020, 78, 316-320.	1.9	32
56	Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. European Urology, 2020, 78, 327-332.	1.9	18
57	Clinical utility of PSAD combined with PI-RADS category for the detection of clinically significant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 846.e9-846.e16.	1.6	20
58	Prognostic value of the SPOP mutant genomic subclass in prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 418-422.	1.6	8
59	Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. Prostate Cancer and Prostatic Diseases, 2020, 23, 646-653.	3.9	17
60	Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Annals of Oncology, 2020, 31, 745-759.	1.2	770
61	Diagnostic Accuracy of Prostate Biopsy for Detecting Cribriform Gleason Pattern 4 Carcinoma and Intraductal Carcinoma in Paired Radical Prostatectomy Specimens: Implications for Active Surveillance. Journal of Urology, 2020, 203, 311-319.	0.4	38
62	Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop. Journal of Urology, 2020, 203, 115-119.	0.4	9
63	Downgrading from Biopsy Grade Group 4 Prostate Cancer in Patients Undergoing Radical Prostatectomy for High or Very High Risk Prostate Cancer. Journal of Urology, 2020, 204, 748-753.	0.4	11
64	A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. Blood Advances, 2020, 4, 181-190.	5.2	16
65	A Rational Approach to Managing Prostate Cancer in an Irrational Time. Oncology, 2020, , 163-163.	0.5	0
66	Reply by Authors. Journal of Urology, 2020, 203, 318-319.	0.4	0
67	Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy. Cancer, 2019, 125, 3853-3863.	4.1	4
68	Rapid and structure-specific cellular uptake of selected steroids. PLoS ONE, 2019, 14, e0224081.	2.5	17
69	Addition of magnetic resonance imaging to real time trans-rectal ultrasound-based treatment planning for prostate implants. Journal of Contemporary Brachytherapy, 2019, 11, 361-369.	0.9	2
70	Association of mTOR Pathway Markers and Clinical Outcomes in Patients with Intermediate-/High-risk Prostate Cancer: Long-Term Analysis. Clinical Genitourinary Cancer, 2019, 17, 366-372.	1.9	1
71	Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer. Investigational New Drugs, 2019, 37, 559-566.	2.6	12
72	Older Age at Diagnosis and Initial Disease Volume Predict Grade Reclassification Risk on Confirmatory Biopsy in Patients Considered for Active Surveillance. Urology, 2019, 130, 106-112.	1.0	3

#	Article	IF	Citations
73	Atypical intraductal proliferation detected in prostate needle biopsy is a marker of unsampled intraductal carcinoma and other adverse pathological features: a prospective clinicopathological study of 62 cases with emphasis on pathological outcomes. Histopathology, 2019, 75, 346-353.	2.9	22
74	Assessing the relationship between statin use and oncologic outcomes among men electing active surveillance for localized prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 617-623.	3.9	2
75	Time to initial cancer treatment in the United States and association with survival over time: An observational study. PLoS ONE, 2019, 14, e0213209.	2.5	179
76	Correlation between MRI phenotypes and a genomic classifier of prostate cancer: preliminary findings. European Radiology, 2019, 29, 4861-4870.	4.5	23
77	A Case of Metastatic Prostate Cancer to the Urethra That Resolved After Androgen Deprivation Therapy. Urology, 2019, 129, e4-e5.	1.0	5
78	Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy. Oncogene, 2019, 38, 4496-4511.	5.9	8
79	ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. Cancer Cell, 2019, 35, 401-413.e6.	16.8	127
80	Validation of an epigenetic field of susceptibility to detect significant prostate cancer from non-tumor biopsies. Clinical Epigenetics, 2019, 11, 168.	4.1	7
81	Perioperative Troponin is a Predictor of Both Short- and Intermediate-term Mortality Among Patients Undergoing Major Urologic Surgery. Urology, 2019, 123, 108-113.	1.0	1
82	Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer. Journal of the National Cancer Institute, 2019, 111, 557-567.	6.3	21
83	Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance. Prostate Cancer and Prostatic Diseases, 2019, 22, 399-405.	3.9	53
84	Outcomes of very highâ€risk prostate cancer after radical prostatectomy: Validation study from 3 centers. Cancer, 2019, 125, 391-397.	4.1	37
85	Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 584-590.	2.5	8
86	Does time from diagnosis to treatment of high- or very-high-risk prostate cancer affect outcome?. BJU International, 2019, 124, 282-289.	2.5	13
87	Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 292-302.	3.9	10
88	The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. Journal of the National Cancer Institute, 2019, 111, 301-310.	6.3	142
89	Clinical Validation of IsoPSAâ„¢, a Single Parameter, Structure Based Assay for Improved Detection of High Grade Prostate Cancer. Journal of Urology, 2019, 201, 1115-1120.	0.4	13
90	African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome. Journal of Urology, 2019, 202, 247-255.	0.4	19

#	Article	IF	Citations
91	SPARED Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer. Journal of Urology, 2019, 202, 952-958.	0.4	8
92	Genome-wide cell-free DNA (cfDNA) methylation signatures and effect on tissue of origin (TOO) performance.. Journal of Clinical Oncology, 2019, 37, 3049-3049.	1.6	16
93	The Circulating Cell-free Genome Atlas (CCGA) Study: Follow-up (F/U) on non-cancer participants with cancer-like cell-free DNA signals.. Journal of Clinical Oncology, 2019, 37, 5574-5574.	1.6	5
94	Radiomic features derived from pre-operative multi-parametric MRI of prostate cancer are associated with Decipher risk score. , 2019, , .		0
95	Editorial Comment. Journal of Urology, 2019, 202, 101-101.	0.4	0
96	Editorial Comment. Journal of Urology, 2019, 202, 701-701.	0.4	0
97	Reply by Authors. Journal of Urology, 2019, 202, 958-958.	0.4	0
98	Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. JAMA - Journal of the American Medical Association, 2018, 319, 896.	7.4	252
99	Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Nature Communications, 2018, 9, 556.	12.8	188
100	Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer. EBioMedicine, 2018, 31, 182-189.	6.1	132
101	Editorial Comment. Journal of Urology, 2018, 199, 1474-1474.	0.4	0
102	Robotic Single-port Partial Prostatectomy for Anterior Tumors: Transvesical Approach. Urology, 2018, 118, 242.	1.0	6
103	Reducing Overutilization of Preoperative Medical Referrals Among Patients Undergoing Radical Cystectomy Using an Evidence-based Algorithm. Urology, 2018, 114, 71-76.	1.0	4
104	Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. European Urology, 2018, 73, 168-175.	1.9	53
105	Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer. European Urology, 2018, 73, 524-532.	1.9	60
106	Validation of GEMCaP as a DNA Based Biomarker to Predict Prostate Cancer Recurrence after Radical Prostatectomy. Journal of Urology, 2018, 199, 719-725.	0.4	4
107	Genomic Scores are Independent of Disease Volume in Men with Favorable Risk Prostate Cancer: Implications for Choosing Men for Active Surveillance. Journal of Urology, 2018, 199, 438-444.	0.4	11
108	Identifying Institutional Causes of Delay to Radical Cystectomy among Patients with High Risk Bladder Cancer Treated at a Tertiary Referral Center Using Process Map Analysis. Urology Practice, 2018, 5, 383-390.	0.5	3

#	Article	IF	Citations
109	Impact of 5Î±-Reductase Inhibitors on Disease Reclassification among Men on Active Surveillance for Localized Prostate Cancer with Favorable Features. Journal of Urology, 2018, 199, 445-452.	0.4	9
110	Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer. JCO Precision Oncology, 2018, 2018, 1-13.	3.0	29
111	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. Journal of Clinical Oncology, 2018, 36, 414-424.	1.6	155
112	Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. Journal of Clinical Oncology, 2018, 36, 581-590.	1.6	162
113	A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Utility of Tacrolimus (FK506) for the Prevention of Erectile Dysfunction Following Bilateral Nerve-Sparing Radical Prostatectomy. Journal of Sexual Medicine, 2018, 15, 1293-1299.	0.6	15
114	Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy. Clinical Cancer Research, 2018, 24, 3908-3916.	7.0	24
115	Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy. European Urology Oncology, 2018, 1, 143-148.	5.4	19
116	The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials. Cancer Epidemiology, 2018, 55, 117-122.	1.9	3
117	Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study. International Journal of Radiation Oncology Biology Physics, 2018, 101, 883-888.	0.8	10
118	Testing of a Tool for Prostate Cancer Screening Discussions in Primary Care. Frontiers in Oncology, 2018, 8, 238.	2.8	3
119	Editorial Comment. Journal of Urology, 2018, 200, 572-572.	0.4	0
120	IFNL4-Î”G Allele Is Associated with an Interferon Signature in Tumors and Survival of African-American Men with Prostate Cancer. Clinical Cancer Research, 2018, 24, 5471-5481.	7.0	37
121	Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1376-1383.	2.5	9
122	The 17-Gene Genomic Prostate Score Assay Predicts Outcome After Radical Prostatectomy Independent of PTEN Status. Urology, 2018, 121, 132-138.	1.0	5
123	Development of a comprehensive cell-free DNA (cfDNA) assay for early detection of multiple tumor types: The Circulating Cell-free Genome Atlas (CCGA) study.. Journal of Clinical Oncology, 2018, 36, 12021-12021.	1.6	50
124	Tissue-Based Markers for Risk Prediction. Current Clinical Urology, 2018, , 121-133.	0.0	0
125	PSA screening: Back to the future. Cleveland Clinic Journal of Medicine, 2018, 85, 881-883.	1.3	0
126	Effects of Castration on BPH. Journal of Urology, 2017, 197, S76-S77.	0.4	0

#	Article	IF	Citations
127	Evaluation of a 24â€gene signature for prognosis of metastatic events and prostate cancerâ€specific mortality. BJU International, 2017, 119, 961-967.	2.5	6
128	Prostate cancer screening practices in a large, integrated health system: 2007â€“2014. BJU International, 2017, 120, 257-264.	2.5	29
129	Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. JAMA Oncology, 2017, 3, 1663.	7.1	219
130	The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary Report. European Urology, 2017, 72, 942-949.	1.9	35
131	Clinical and molecular rationale to retain the cancer descriptor for Gleason score 6 disease. Nature Reviews Urology, 2017, 14, 59-64.	3.8	3
132	Prognostic Significance of a Negative Confirmatory Biopsy on Reclassification Among Men on Active Surveillance. Urology, 2017, 107, 184-189.	1.0	9
133	Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. European Urology, 2017, 72, 845-852.	1.9	79
134	Accuracy and Interobserver Agreement for Prostate Imaging Reporting and Data System, Version 2, for the Characterization of Lesions Identified on Multiparametric MRI of the Prostate. American Journal of Roentgenology, 2017, 209, 339-349.	2.2	63
135	Intermediate-Term Outcomes for Men with Very Low/Low and Intermediate/High Risk Prostate Cancer Managed by Active Surveillance. Journal of Urology, 2017, 198, 591-599.	0.4	36
136	External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life. International Journal of Radiation Oncology Biology Physics, 2017, 98, 304-317.	0.8	25
137	Editorial Comment. Journal of Urology, 2017, 197, 1040-1040.	0.4	0
138	Phase 2 Study of ^{99m}Tc-Trofolastat SPECT/CT to Identify and Localize Prostate Cancer in Intermediate- and High-Risk Patients Undergoing Radical Prostatectomy and Extended Pelvic LN Dissection. Journal of Nuclear Medicine, 2017, 58, 1408-1413.	5.0	63
139	Access to high-volume surgeons and the opportunity cost of performing radical prostatectomy by low-volume providers. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 459.e15-459.e24.	1.6	3
140	MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2. Cancer Research, 2017, 77, 1021-1034.	0.9	94
141	A 72-Year-Old Man With Obstructive Voiding Symptoms, Elevated Prostate-specific Antigen Level, and Nodular Digital Rectal Examination. Urology, 2017, 104, 22-24.	1.0	0
142	A Comparison Between Low-Dose-Rate Brachytherapy With or Without Androgen Deprivation, External Beam Radiation Therapy With or Without Androgen Deprivation, and Radical Prostatectomy With or Without Adjuvant or Salvage Radiation Therapy for High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 97, 962-975.	0.8	45
143	Dynamic Contrast Enhanced Magnetic Resonance Imaging Improves Classification of Prostate Lesions: A Study of Pathological Outcomes on Targeted Prostate Biopsy. Journal of Urology, 2017, 198, 1301-1308.	0.4	22
144	Direct Metabolic Interrogation of Dihydrotestosterone Biosynthesis from Adrenal Precursors in Primary Prostatectomy Tissues. Clinical Cancer Research, 2017, 23, 6351-6362.	7.0	35

#	Article	IF	Citations
145	A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1549-1557.	2.5	61
146	Reply to Parham Habibzadeh and Farrokh Habibzadeh's Letter to the Editor re: Eric A. Klein, Arnon Chait, Jason M. Hafron, et al. The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary Report. Eur Urol 2017;72:942â€“9. The Most Appropriate IsoPSA Cutoff for Diagnosis of Prostate Cancer. European Urology, 2017, 72, 1.	1.9	0
147	Reply to Lars Egevad, Hemamali Samaratunga, John R. Srigley, Brett Delahunt's Letter to the Editor re: Anthony Zietman, Joseph Smith, Eric Klein, Michael Droller, Prokar Dasgupta, James Catto. Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required. Eur Urol 2016;70:1. European Urology, 2017, 71, e54.	1.9	0
148	Outcomes of Active Surveillance after Initial Surveillance Prostate Biopsy. Journal of Urology, 2017, 197, 84-89.	0.4	8
149	Molecular Analysis of Low Grade Prostate Cancer Using a Genomic Classifier of Metastatic Potential. Journal of Urology, 2017, 197, 122-128.	0.4	33
150	Relief of Urinary Symptom Burden after Primary Prostate Cancer Treatment. Journal of Urology, 2017, 197, 376-384.	0.4	18
151	Gene Expression Testing as a Predictor of Adverse Pathology after Radical Prostatectomy: Implications for Choosing Patients for Active Surveillance. Urology Practice, 2017, 4, 140-148.	0.5	0
152	Is a behavioral treatment for urinary incontinence beneficial to prostate cancer survivors as a follow-up care?. Journal of Cancer Survivorship, 2017, 11, 24-31.	2.9	9
153	The worldâ€™s first single-room proton therapy facility: Two-year experience. Practical Radiation Oncology, 2017, 7, e71-e76.	2.1	21
154	Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry. Journal of the National Cancer Institute, 2017, 109, .	6.3	57
155	Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer. ELife, 2017, 6, .	6.0	83
156	Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients. Oncotarget, 2017, 8, 50804-50813.	1.8	29
157	Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. Journal of Clinical Oncology, 2017, 35, 1991-1998.	1.6	176
158	Discovery and fine-mapping of adiposity loci using high density imputation of genome-wide association studies in individuals of African ancestry: African Ancestry Anthropometry Genetics Consortium. PLoS Genetics, 2017, 13, e1006719.	3.5	98
159	Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance. Oncotarget, 2017, 8, 18949-18967.	1.8	47
160	OncotypeDx genomic scores independent of disease volume in men with favorable-risk prostate cancer.. Journal of Clinical Oncology, 2017, 35, 93-93.	1.6	0
161	Predicting disease progression in men with localized high risk prostate cancer undergoing radical prostatectomy.. Journal of Clinical Oncology, 2017, 35, 51-51.	1.6	0
162	Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. Oncotarget, 2016, 7, 66328-66343.	1.8	88

#	Article	IF	Citations
163	Molecular markers in urologic oncology. Current Opinion in Urology, 2016, 26, 225-230.	1.8	7
164	Opportunities and challenges in incorporating ancillary studies into a cancer prevention randomized clinical trial. Trials, 2016, 17, 400.	1.6	2
165	In Reply to Samaratunga etÂal. International Journal of Radiation Oncology Biology Physics, 2016, 96, 1127-1128.	0.8	0
166	New Gleason grading system: Statement from the Editors of six journals. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 253.	1.6	9
167	Stage Grouping. Journal of Urology, 2016, 195, 1723-1723.	0.4	9
168	Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes. International Journal of Radiation Oncology Biology Physics, 2016, 95, 960-964.	0.8	46
169	Selenium- or Vitamin Eâ€“Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1050-1058.	2.5	55
170	A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1609-1618.	2.5	18
171	An Approach Using PSA Levels of 1.5â€‰ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care. Urology, 2016, 96, 116-120.	1.0	11
172	Re: Samaratunga et al: Consensus Guidelines for Reporting Prostate Cancer Gleason Grade. Urology, 2016, 96, 179.	1.0	0
173	HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. Lancet Oncology, The, 2016, 17, 1435-1444.	10.7	107
174	Consensus guidelines for reporting prostate cancer Gleason Grade. BJU International, 2016, 117, 849-849.	2.5	11
175	Consensus guidelines for reporting prostate cancer Gleason Grade. BJU International, 2016, 118, E1-2.	2.5	10
176	Posttreatment Prostate-Specific Antigen 6ÂMonths After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasisâ€“Free Survival and Prostate Cancerâ€“Specific Mortality. International Journal of Radiation Oncology Biology Physics, 2016, 96, 617-623.	0.8	12
177	Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. Nature Communications, 2016, 7, 10979.	12.8	50
178	Introduction to Big Data in Radiation Oncology: Exploring Opportunities for Research, Quality Assessment, and Clinical Care. International Journal of Radiation Oncology Biology Physics, 2016, 95, 871-872.	0.8	30
179	Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome. Cancer Research, 2016, 76, 4948-4958.	0.9	147
180	A Case of Prostate Cancer in Lynch Syndrome. Urology, 2016, 95, 25-28.	1.0	0

#	Article	IF	Citations
181	Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine, 2016, 7, 85-93.	6.1	6
182	Editorial Statement on Gleason Scoring for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1092.	0.8	2
183	Decipher Genomic Classifier Measured on Prostate Biopsy Predicts Metastasis Risk. Urology, 2016, 90, 148-152.	1.0	138
184	Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. JAMA Oncology, 2016, 2, 471.	7.1	46
185	Racial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor Location. European Urology, 2016, 70, 14-17.	1.9	79
186	The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer. Clinical Cancer Research, 2016, 22, 1777-1786.	7.0	42
187	Consensus Guidelines for Reporting Prostate Cancer Gleason Grade. Urology, 2016, 93, 1.	1.0	9
188	Effect of long-term vitamin E and selenium supplementation on urine F2-isoprostanes, a biomarker of oxidative stress. Free Radical Biology and Medicine, 2016, 95, 349-356.	2.9	24
189	Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required. European Urology, 2016, 70, 1.	1.9	16
190	Prostate Cancer Susceptibility in Men of African Ancestry at 8q24. Journal of the National Cancer Institute, 2016, 108, djv431.	6.3	111
191	Outcomes for prostate glands >60Âcc treated with low-dose-rate brachytherapy. Brachytherapy, 2016, 15, 163-168.	0.5	5
192	More Favorable Pathological Outcomes in Men with Low Risk Prostate Cancer Diagnosed on Repeat versus Initial Transrectal Ultrasound Guided Prostate Biopsy. Journal of Urology, 2016, 195, 1767-1772.	0.4	13
193	A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. European Urology, 2016, 69, 428-435.	1.9	1,039
194	Gene expression in normal-appearing tissue adjacent to prostate cancers are predictive of clinical outcome: evidence for a biologically meaningful field effect. Oncotarget, 2016, 7, 33855-33865.	1.8	22
195	Applying precision medicine to the active surveillance of prostate cancer. Cancer, 2015, 121, 3403-3411.	4.1	19
196	Does cumulative prostate cancer length (<scp>CCL</scp>) in prostate biopsies improve prediction of clinically insignificant cancer at radical prostatectomy in patients eligible for active surveillance?. BJU International, 2015, 116, 220-229.	2.5	5
197	Vitamin D Metabolic Pathway Genes and Pancreatic Cancer Risk. PLoS ONE, 2015, 10, e0117574.	2.5	29
198	A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma. Journal of Urology, 2015, 194, 297-303.	0.4	80

#	Article	IF	Citations
199	Long-Term Efficacy and Toxicity of Low-Dose-Rate 125 I Prostate Brachytherapy as Monotherapy in Low-, Intermediate-, and High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 92, 884-893.	0.8	63
200	The TMPRSS2â€“ERG Gene Fusion Blocks XRCC4-Mediated Nonhomologous End-Joining Repair and Radiosensitizes Prostate Cancer Cells to PARP Inhibition. Molecular Cancer Therapeutics, 2015, 14, 1896-1906.	4.1	34
201	A randomized controlled trial of vitamin E and selenium on rate of decline in lung function. Respiratory Research, 2015, 16, 35.	3.6	16
202	Influence of zonal dosimetry on prostate brachytherapy outcomes. Journal of Contemporary Brachytherapy, 2015, 1, 17-22.	0.9	1
203	Development and Clinical Validation of an In Situ Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer. Clinical Cancer Research, 2015, 21, 2591-2600.	7.0	157
204	Re: Long-term Follow-up of a Large Active Surveillance Cohort of Patients with Prostate Cancer. European Urology, 2015, 68, 906-907.	1.9	3
205	Are Biochemical Recurrence Outcomes Similar After Radical Prostatectomy and Radiation Therapy? Analysis of Prostate Cancerâ€“Specific Mortality by Nomogram-predicted Risks of Biochemical Recurrence. European Urology, 2015, 67, 204-209.	1.9	38
206	A Genomic Classifier Improves Prediction of Metastatic Disease Within 5 Years After Surgery in Node-negative High-risk Prostate Cancer Patients Managed by Radical Prostatectomy Without Adjuvant Therapy. European Urology, 2015, 67, 778-786.	1.9	162
207	Generalizability of established prostate cancer risk variants in men of <scp>A</scp>frican ancestry. International Journal of Cancer, 2015, 136, 1210-1217.	5.1	62
208	Nomogram Predicting Prostate Cancerâ€“specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy. European Urology, 2015, 67, 1160-1167.	1.9	192
209	Seeing and Not Believing: Oligometastases and the Future of Metastatic Prostate Cancer. European Urology, 2015, 67, 864-865.	1.9	5
210	Characterization of 1577 Primary Prostate Cancers Reveals Novel Biological and Clinicopathologic Insights into Molecular Subtypes. European Urology, 2015, 68, 555-567.	1.9	125
211	Integration of multiethnic fine-mapping and genomic annotation to prioritize candidate functional SNPs at prostate cancer susceptibility regions. Human Molecular Genetics, 2015, 24, 5603-5618.	2.9	50
212	Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer. Journal of Clinical Oncology, 2015, 33, 2789-2796.	1.6	127
213	Safety and efficacy of iodine-125 permanent prostate brachytherapy in patients with J-pouch anastomosis after total colectomy for ulcerative colitis. Practical Radiation Oncology, 2015, 5, e437-e442.	2.1	16
214	MR-TRUS fusion biopsyâ€”defining a new standard. Nature Reviews Clinical Oncology, 2015, 12, 253-254.	27.6	6
215	Age-Related Cataract in Men in the Selenium and Vitamin E Cancer Prevention Trial Eye Endpoints Study. JAMA Ophthalmology, 2015, 133, 17.	2.5	38
216	For Single Dosing, Levofloxacin Is Superior to Ciprofloxacin When Combined With an Aminoglycoside in Preventing Severe Infections After Prostate Biopsy. Urology, 2015, 85, 1241-1246.	1.0	12

#	Article	IF	Citations
217	Effects of Patient Centered Interventions on Persistent Urinary Incontinence after Prostate Cancer Treatment: A Randomized, Controlled Trial. Journal of Urology, 2015, 194, 1675-1681.	0.4	26
218	Minimally Important Difference for the Expanded Prostate Cancer Index Composite Short Form. Urology, 2015, 85, 101-106.	1.0	241
219	RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. Lancet Oncology, The, 2014, 15, 1469-1480.	10.7	226
220	Clinical Validation of an Epigenetic Assay to Predict Negative Histopathological Results in Repeat Prostate Biopsies. Journal of Urology, 2014, 192, 1081-1087.	0.4	196
221	Statin Drug Use is Not Associated with Prostate Cancer Risk in Men Who are Regularly Screened. Journal of Urology, 2014, 192, 379-384.	0.4	43
222	Baseline Selenium Status and Effects of Selenium and Vitamin E Supplementation on Prostate Cancer Risk. Journal of the National Cancer Institute, 2014, 106, djt456.	6.3	221
223	Do Margins Matter? The Influence of Positive Surgical Margins on Prostate Cancerâ€“Specific Mortality. European Urology, 2014, 65, 675-680.	1.9	77
224	Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Nature Genetics, 2014, 46, 994-1000.	21.4	294
225	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nature Genetics, 2014, 46, 1103-1109.	21.4	408
226	Plasma Tocopherols and Risk of Prostate Cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Prevention Research, 2014, 7, 886-895.	1.5	58
227	A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling. European Urology, 2014, 66, 550-560.	1.9	553
228	A Commentary on PSA Velocity and Doubling Time for Clinical Decisions in Prostate Cancer. Urology, 2014, 83, 592-598.	1.0	43
229	Future Directions From Past Experience: A Century of Prostate Radiotherapy. Clinical Genitourinary Cancer, 2014, 12, 13-20.	1.9	12
230	Neoadjuvant Androgen Deprivation Therapy Leads to Immediate Impairment of Vitality/Hormonal and Sexual Quality of Life: Results of a Multicenter Prospective Study. Urology, 2013, 82, 1363-1369.	1.0	20
231	2131 DEVELOPMENT AND VALIDATION OF THE BIOPSY-BASED GENOMIC PROSTATE SCORE (GPS) AS A PREDICTOR OF HIGH GRADE OR EXTRACAPSULAR PROSTATE CANCER TO IMPROVE PATIENT SELECTION FOR ACTIVE SURVEILLANCE. Journal of Urology, 2013, 189, .	0.4	19
232	Mortality After Prostate Cancer Treatment with Radical Prostatectomy, External-Beam Radiation Therapy, or Brachytherapy in Men Without Comorbidity. European Urology, 2013, 64, 372-378.	1.9	71
233	Adjuvant and Salvage Radiotherapy After Prostatectomy: AUA/ASTRO Guideline. Journal of Urology, 2013, 190, 441-449.	0.4	368
234	A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nature Genetics, 2013, 45, 690-696.	21.4	232

#	Article	IF	Citations
235	HOXB13 Mutation and Prostate Cancer: Studies of Siblings and Aggressive Disease. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 675-680.	2.5	40
236	Moving a randomized clinical trial into an observational cohort. Clinical Trials, 2013, 10, 131-142.	1.6	17
237	Analytical validation of the Oncotype DX prostate cancer assay â€“ a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics, 2013, 14, 690.	2.8	277
238	PARP Inhibition Sensitizes to Low Dose-Rate Radiation TMPRSS2-ERG Fusion Gene-Expressing and PTEN-Deficient Prostate Cancer Cells. PLoS ONE, 2013, 8, e60408.	2.5	102
239	Long-Term (10-Year) Gastrointestinal and Genitourinary Toxicity after Treatment with External Beam Radiotherapy, Radical Prostatectomy, or Brachytherapy for Prostate Cancer. Prostate Cancer, 2012, 2012, 1-7.	0.6	33
240	Early infectious complications with transponder placement for external beam radiation therapy for prostate cancer. BJU International, 2012, 110, 834-838.	2.5	7
241	Impact of different definitions of high-risk prostate cancer on survival after radical prostatectomy.. Journal of Clinical Oncology, 2012, 30, 113-113.	1.6	0
242	Avoiding Androgen Deprivation Therapy in Men With High-risk Prostate Cancer: The Role of Radical Prostatectomy as Initial Treatment. Urology, 2011, 77, 946-950.	1.0	20
243	Predicting 15-Year Prostate Cancer Specific Mortality After Radical Prostatectomy. Journal of Urology, 2011, 185, 869-875.	0.4	574
244	Clinical Investigations Prophylactic urethral stenting with MemokathÂ® 028SW in prostate cancer patients undergoing prostate 125I seed implants: phase I/II study. Journal of Contemporary Brachytherapy, 2011, 1, 18-22.	0.9	3
245	Pathological results and rates of treatment failure in highâ€risk prostate cancer patients after radical prostatectomy. BJU International, 2011, 107, 765-770.	2.5	120
246	TMPRSS2â€“ERG gene fusion prevalence and class are significantly different in prostate cancer of caucasian, africanâ€american and japanese patients. Prostate, 2011, 71, 489-497.	2.3	239
247	PSA Bounce and Biochemical Failure After Brachytherapy for Prostate Cancer: A Study of 820 Patients With a Minimum of 3 Years ofÂFollow-Up. International Journal of Radiation Oncology Biology Physics, 2011, 80, 735-741.	0.8	60
248	Vitamin E and the Risk of Prostate Cancer. JAMA - Journal of the American Medical Association, 2011, 306, 1549.	7.4	1,458
249	Prediction of Erectile Function Following Treatment for Prostate Cancer. JAMA - Journal of the American Medical Association, 2011, 306, 1205.	7.4	253
250	ERG rearrangement is present in a subset of transition zone prostatic tumors. Modern Pathology, 2010, 23, 1499-1506.	5.5	52
251	The Epstein Criteria Predict for Organ-Confined But Not Insignificant Disease and a High Likelihood of Cure at Radical Prostatectomy. European Urology, 2010, 58, 90-95.	1.9	67
252	The Importance of Serum Prostate-specific Antigen Testing Frequency in Assessing Biochemical and Clinical Failure After Prostate Cancer Treatment. Urology, 2010, 75, 467-471.	1.0	21

#	Article	IF	Citations
253	Five Year Biochemical Recurrence Free Survival for Intermediate Risk Prostate Cancer After Radical Prostatectomy, External Beam Radiation Therapy or Permanent Seed Implantation. Urology, 2010, 76, 1251-1257.	1.0	64
254	Prostate Cancerâ€"Specific Mortality After Radical Prostatectomy for Patients Treated in the Prostate-Specific Antigen Era. Journal of Clinical Oncology, 2009, 27, 4300-4305.	1.6	417
255	Effect of Selenium and Vitamin E on Risk of Prostate Cancer and Other Cancers. JAMA - Journal of the American Medical Association, 2009, 301, 39.	7.4	1,832
256	Cell-Cycle Control by Physiological Matrix Elasticity and In Vivo Tissue Stiffening. Current Biology, 2009, 19, 1511-1518.	3.9	368
257	Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer. Cancer, 2009, 115, 1005-1010.	4.1	71
258	Lack of pathologic downâ€staging with neoadjuvant chemotherapy for muscleâ€invasive urothelial carcinoma of the bladder. Cancer, 2009, 115, 792-799.	4.1	85
259	A Multi-Institutional Evaluation of Active Surveillance for Low Risk Prostate Cancer. Journal of Urology, 2009, 181, 1635-1641.	0.4	121
260	The Specific Definition of High Risk Prostate Cancer Has Minimal Impact on Biochemical Relapse-Free Survival. Journal of Urology, 2009, 181, 75-80.	0.4	46
261	Prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 494.	1.6	2
262	Quality of Life and Satisfaction with Outcome among Prostate-Cancer Survivors. New England Journal of Medicine, 2008, 358, 1250-1261.	27.0	2,030
263	Clinical and Biological Effects of Neoadjuvant Sargramostim and Thalidomide in Patients with Locally Advanced Prostate Carcinoma. Clinical Cancer Research, 2008, 14, 3052-3059.	7.0	15
264	Predicting the Outcome of Salvage Radiation Therapy for Recurrent Prostate Cancer After Radical Prostatectomy. Journal of Clinical Oncology, 2007, 25, 2035-2041.	1.6	836
265	The Surgical Learning Curve for Prostate Cancer Control After Radical Prostatectomy. Journal of the National Cancer Institute, 2007, 99, 1171-1177.	6.3	368
266	Tumor Volume Does Not Predict for Biochemical Recurrence After Radical Prostatectomy in Patients with Surgical Gleason Score 6 or Less Prostate Cancer. Urology, 2007, 70, 294-298.	1.0	45
267	Neoadjuvant docetaxel treatment for locally advanced prostate cancer. Cancer, 2007, 110, 1248-1254.	4.1	55
268	Hypofractionated Intensity-Modulated Radiotherapy (70 Gy at 2.5 Gy Per Fraction) for Localized Prostate Cancer: Cleveland Clinic Experience. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1424-1430.	0.8	342
269	Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: A prospective analysis. Urology, 2006, 67, 1253-1256.	1.0	86
270	Genetic susceptibility and oxidative stress in prostate cancer: Integrated model with implications for prevention. Urology, 2006, 68, 1145-1151.	1.0	30

#	Article	IF	Citations
271	Improved biochemical relapse-free survival for patients with large/wide glands treated with prostate seed implantation for localized adenocarcinoma of prostate. Urology, 2006, 68, 1237-1241.	1.0	13
272	Is histologic necrosis in the primary tumor of patients with renal-cell carcinoma a predictor for survival?. Nature Clinical Practice Oncology, 2006, 3, 72-73.	4.3	0
273	Chemoprevention of Prostate Cancer. Annual Review of Medicine, 2006, 57, 49-63.	12.2	39
274	Radical prostatectomy versus watchful waiting for early prostate cancer: finally, an answer. Nature Reviews Urology, 2005, 2, 412-413.	1.4	1
275	Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: Final report of a double-blind placebo-controlled randomized study. International Journal of Radiation Oncology Biology Physics, 2005, 62, 164-169.	0.8	69
276	Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute, 2005, 97, 94-102.	6.3	309
277	Postoperative Nomogram Predicting the 10-Year Probability of Prostate Cancer Recurrence After Radical Prostatectomy. Journal of Clinical Oncology, 2005, 23, 7005-7012.	1.6	564
278	Phase III Prostate Cancer Prevention Trials: Are the Costs Justified?. Journal of Clinical Oncology, 2005, 23, 8161-8164.	1.6	28
279	A retrospective comparison of androgen deprivation (AD) vs. no AD among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1347-1350.	0.8	40
280	Selenium: Epidemiology and Basic Science. Journal of Urology, 2004, 171, S50-3; discussion S53.	0.4	93
281	Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology, 2004, 63, 1138-1142.	1.0	140
282	Update on chemoprevention of prostate cancer. Current Opinion in Urology, 2004, 14, 143-149.	1.8	93
283	The Selenium and Vitamin E Cancer Prevention Trial. World Journal of Urology, 2003, 21, 21-27.	2.2	100
284	Localized prostate cancer: radiation or surgery?. Urologic Clinics of North America, 2003, 30, 315-330.	1.8	25
285	Effect of anatomic, procedural, and dosimetric variables on urinary retention after permanent iodine-125 prostate brachytherapy. Urology, 2003, 61, 152-155.	1.0	40
286	Age and PSA predict likelihood of organ-confined disease in men presenting with PSA less than 10 ng/mL: implications for screening. Urology, 2003, 62, 70-74.	1.0	38
287	SELECT: the selenium and vitamin E cancer prevention trial. Urologic Oncology: Seminars and Original Investigations, 2003, 21, 59-65.	1.6	138
288	Clinical Models for Testing Chemopreventative Agents in Prostate Cancer and Overview of SELCT: The Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research, 2003, 163, 212-225.	1.8	19

#	Article	IF	Citations
289	SARCOMATOID TRANSITIONAL CELL CARCINOMA OF BLADDER MANAGED WITH TRANSURETHRAL RESECTION ALONE. Journal of Urology, 2002, 167, 641-642.	0.4	4
290	Comparison of the Efficacy of Local Therapies for Localized Prostate Cancer in the Prostate-Specific Antigen Era: A Large Single-Institution Experience With Radical Prostatectomy and External-Beam Radiotherapy. Journal of Clinical Oncology, 2002, 20, 3376-3385.	1.6	230
291	Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology, 2001, 57, 281-285.	1.0	103
292	SUBTOTAL RADICAL CYSTECTOMY AFTER RADICAL PROSTATECTOMY: A SOURCE OF PELVIC RECURRENCE OF BLADDER CANCER WITH LIFE THREATENING BLEEDING. Journal of Urology, 2001, 166, 988-989.	0.4	0
293	Management of erectile dysfunction following radical prostatectomy. Current Urology Reports, 2001, 2, 495-503.	2.2	63
294	Intermediate-Term Outcome with Radical Prostatectomy for Localized Prostate Cancer: The Cleveland Clinic Experience. Prostate Journal, 2001, 3, 118-125.	0.2	11
295	Replication linkage study for prostate cancer susceptibility genes. Prostate, 2000, 45, 106-114.	2.3	35
296	Dosimetric comparison of pre-planned and or-planned prostate seed brachytherapy. International Journal of Radiation Oncology Biology Physics, 2000, 48, 1241-1244.	0.8	47
297	Acute Complications after Radical Retropubicâ€ƒProstatectomy. Prostate Journal, 2000, 2, 22-26.	0.2	7
298	Defective DNA repair genes in a primary culture of human renal cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2000, 126, 185-190.	2.5	23
299	Extent of extracapsular extension in localized prostate cancer. Urology, 2000, 55, 382-386.	1.0	136
300	EDITORIAL: TRANSRECTAL ULTRASOUND GUIDED PROSTATE BIOPSYâ€"DEFINING A NEW STANDARD. Journal of Urology, 2000, 163, 179-180.	0.4	36
301	RETROPERITONEAL LAPAROSCOPIC RADICAL NEPHRECTOMY: THE CLEVELAND CLINIC EXPERIENCE. Journal of Urology, 2000, 163, 1665-1670.	0.4	212
302	Declining Rates of Extracapsular Extension After Radical Prostatectomy: Evidence for Continued Stage Migration. Journal of Clinical Oncology, 1999, 17, 3167-3172.	1.6	142
303	RACE AS AN INDEPENDENT PREDICTOR OF OUTCOME AFTER TREATMENT FOR LOCALIZED PROSTATE CANCER. Journal of Urology, 1999, 162, 1331-1336.	0.4	37
304	Retroviral transduction of intercellular adhesion molecule-1 enhances endothelial attachment of bladder cancer. Urological Research, 1997, 25, 401-405.	1.5	6
305	Indications for excluding the seminal vesicles when treating clinically localized prostatic adenocarcinoma with radiotherapy alone. International Journal of Radiation Oncology Biology Physics, 1997, 37, 871-876.	0.8	51
306	Editorial: Can Prostate Specific Antigen Derivatives Reduce the Frequency of Unnecessary Prostate Biopsies?. Journal of Urology, 1996, 156, 443-444.	0.4	5

#	Article	IF	Citations
307	The Le Bag Orthotopic Urinary Diversion. Journal of Urology, 1996, 156, 926-930.	0.4	32
308	Editorial: Prostate Cancer. Journal of Urology, 1995, 154, 143-144.	0.4	2
309	Safety of Transurethral Surgery in the Early Postoperative Period Following an Open Cardiac Procedure. Journal of Urology, 1994, 151, 902-904.	0.4	0
310	Complications of Nephron Sparing Surgery for Renal Tumors. Journal of Urology, 1994, 151, 1177-1180.	0.4	253
311	Modified apical dissection for early continence after radical prostatectomy. Prostate, 1993, 22, 217-223.	2.3	22
312	Management of Renal Cell Carcinoma with Coexistent Renal Artery Disease. Journal of Urology, 1993, 150, 808-813.	0.4	18
313	Interleukin 7 enhances the proliferation and effector function of tumorâ€infiltrating lymphocytes from renalâ€cell carcinoma. International Journal of Cancer, 1993, 53, 941-947.	5.1	26
314	Functional Equivalence of End and Loop Ileal Conduit Stomas. Journal of Urology, 1992, 147, 582-586.	0.4	11
315	Early Continence after Radical Prostatectomy. Journal of Urology, 1992, 148, 92-95.	0.4	106
316	Genetics of transitional cell carcinoma. Journal of Surgical Oncology, 1992, 8, 260-266.	1.4	2
317	Suprapubic Approach for Bilateral Orchiectomy and Placement of Testicular Prostheses. Journal of Urology, 1990, 143, 765-766.	0.4	1
318	Noninvasive Testicular Screening in Childhood Leukemia. Journal of Urology, 1986, 136, 864-866.	0.4	9
319	Jejunal Conduit Urinary Diversion. Journal of Urology, 1986, 135, 244-246.	0.4	47
320	Retained Straight Catheter: Complication of Clean Intermittent Catheterization. Journal of Urology, 1986, 135, 780-781.	0.4	13
321	Priapism Associated with the Use of Intravenous Fat Emulsion: Case Reports and Postulated Pathogenesis. Journal of Urology, 1985, 133, 857-859.	0.4	38